Albireo Pharma Inc

-0.65 (-2.22%)
Products, Regulatory

Albireo Gets European Marketing Authorization Of Bylvay

Published: 07/19/2021 12:25 GMT
Albireo Pharma Inc (ALBO) - Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (pfic).
Albireo Pharma Inc - European Commission (ec) Decision Based on Data From Largest Phase 3 Pfic Trial to Date.
Albireo Pharma Inc - U.S. FDA Has Set an Action Date of July 20, 2021, Under Prescription Drug User Fee Act.
Albireo Pharma Inc - German Price Listing Followed by Commercial Launch Expected in September.
Albireo Pharma Inc - Topline Data From Assert Trial is Expected in 2022, and Data From Bold Trial is Expected in 2024.